Kewaunee Scientific (KEQU)
Market Price (12/4/2025): $38.88 | Market Cap: $110.8 MilSector: Consumer Discretionary | Industry: Household Appliances
Kewaunee Scientific (KEQU)
Market Price (12/4/2025): $38.88Market Cap: $110.8 MilSector: Consumer DiscretionaryIndustry: Household Appliances
Investment Highlights
Why It Matters
Which of these 2 stories sounds closer for this stock?
1. Generates cash flow
The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.
2. Riding a trend
Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1%, FCF Yield is 11% | |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30% | |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 7.4%, ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is 3.1%, FCF Yield is 11% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 30% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Advanced Diagnostics, Show more. |
Valuation, Metrics & Events
KEQU Stock
Why The Stock Moved
Qualitative Assessment
AI Generated Analysis | Feedback
1. Negative Investor Reaction to Q1 Fiscal Year 2026 Earnings.
Kewaunee Scientific reported its first-quarter fiscal year 2026 results on September 10, 2025, which included significant increases in sales, net earnings, and diluted earnings per share. However, despite these positive top and bottom-line figures, the stock experienced a substantial decline of 19.7% following the earnings report, indicating that investor expectations might not have been met or that underlying concerns overshadowed the reported growth.
2. Persistent Concerns Regarding Profitability Compression from Acquisition and Integration Costs.
Earlier financial reports for Q3 Fiscal Year 2025 (ending January 31, 2025) highlighted that GAAP profitability was compressed due to costs associated with the acquisition and integration of Nu Aire. If these concerns about the impact of acquisition and integration expenses on overall profitability persisted or were emphasized during the Q1 Fiscal Year 2026 discussions, they likely contributed to a negative outlook throughout the August to December 2025 period.
Stock Movement Drivers
Return vs. Risk
Price Returns Compared
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| KEQU Return | -7% | 2% | 26% | 82% | 113% | -38% | 183% |
| Peers Return | 17% | 3% | -13% | -6% | 2% | -19% | -18% |
| S&P 500 Return | 16% | 27% | -19% | 24% | 23% | 16% | 112% |
Monthly Win Rates [3] | |||||||
| KEQU Win Rate | 33% | 25% | 42% | 67% | 67% | 40% | |
| Peers Win Rate | 27% | 22% | 15% | 27% | 32% | 40% | |
| S&P 500 Win Rate | 58% | 75% | 42% | 67% | 75% | 70% | |
Max Drawdowns [4] | |||||||
| KEQU Max Drawdown | -47% | -8% | 0% | -8% | -4% | -50% | |
| Peers Max Drawdown | -18% | -5% | -18% | -13% | -24% | -31% | |
| S&P 500 Max Drawdown | -31% | -1% | -25% | -1% | -2% | -15% | |
[1] Cumulative total returns since the beginning of 2020
[2] Peers: SN, IRBT, ALH, XWIN, WHR.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)
How Low Can It Go
| Event | KEQU | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -26.3% | -25.4% |
| % Gain to Breakeven | 35.6% | 34.1% |
| Time to Breakeven | 139 days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -47.4% | -33.9% |
| % Gain to Breakeven | 90.2% | 51.3% |
| Time to Breakeven | 446 days | 148 days |
| 2018 Correction | ||
| % Loss | -64.6% | -19.8% |
| % Gain to Breakeven | 182.7% | 24.7% |
| Time to Breakeven | 1602 days | 120 days |
| 2008 Global Financial Crisis | ||
| % Loss | -67.7% | -56.8% |
| % Gain to Breakeven | 209.5% | 131.3% |
| Time to Breakeven | 2797 days | 1480 days |
Compare to SN, IRBT, ALH, XWIN, WHR
In The Past
Kewaunee Scientific's stock fell -26.3% during the 2022 Inflation Shock from a high on 8/25/2022. A -26.3% loss requires a 35.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth over time.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Latest Trefis Analyses
| Title | Topic | |
|---|---|---|
| DASHBOARDS | ||
| Can Kewaunee Scientific Stock Recover If Markets Fall? | Return |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select past ideas related to KEQU. For more, see Trefis Trade Ideas.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BBWI | Bath & Body Works | Dip Buy | DB | Insider Buys | Low D/EDip Buy with Strong Insider BuyingBuying dips for companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 6.8% | 6.8% | 0.0% |
| 11262025 | HRB | H&R Block | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.5% | 0.5% | 0.0% |
| 11262025 | LRN | Stride | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -2.6% | -2.6% | -2.6% |
| 11212025 | ABNB | Airbnb | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.7% | 3.7% | 0.0% |
| 11212025 | MTN | Vail Resorts | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 1.3% | 1.3% | -1.6% |
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 11302025 | BBWI | Bath & Body Works | Dip Buy | DB | Insider Buys | Low D/EDip Buy with Strong Insider BuyingBuying dips for companies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 6.8% | 6.8% | 0.0% |
| 11262025 | HRB | H&R Block | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.5% | 0.5% | 0.0% |
| 11262025 | LRN | Stride | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | -2.6% | -2.6% | -2.6% |
| 11212025 | ABNB | Airbnb | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.7% | 3.7% | 0.0% |
| 11212025 | MTN | Vail Resorts | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 1.3% | 1.3% | -1.6% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons for Kewaunee Scientific
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 30.27 |
| Mkt Cap | 2.3 |
| Rev LTM | 547 |
| Op Inc LTM | 20 |
| FCF LTM | 19 |
| FCF 3Y Avg | 7 |
| CFO LTM | 21 |
| CFO 3Y Avg | 11 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -0.0% |
| Rev Chg 3Y Avg | -9.0% |
| Rev Chg Q | 1.0% |
| QoQ Delta Rev Chg LTM | 0.3% |
| Op Mgn LTM | 5.3% |
| Op Mgn 3Y Avg | 5.1% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 2.8% |
| CFO/Rev 3Y Avg | 4.1% |
| FCF/Rev LTM | 0.4% |
| FCF/Rev 3Y Avg | 1.3% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 2.3 |
| P/S | 0.5 |
| P/EBIT | 8.6 |
| P/E | 6.5 |
| P/CFO | 9.0 |
| Total Yield | 3.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 1.8% |
| D/E | 1.1 |
| Net D/E | 0.9 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 15.4% |
| 3M Rtn | -8.7% |
| 6M Rtn | 1.4% |
| 12M Rtn | -15.0% |
| 3Y Rtn | -33.5% |
| 1M Excs Rtn | 15.5% |
| 3M Excs Rtn | -16.5% |
| 6M Excs Rtn | -13.3% |
| 12M Excs Rtn | -29.4% |
| 3Y Excs Rtn | -105.3% |
Returns Analyses
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 7312025 | 9122025 | 10-Q 7/31/2025 |
| 4302025 | 7022025 | 10-K 4/30/2025 |
| 1312025 | 3142025 | 10-Q 1/31/2025 |
| 10312024 | 12132024 | 10-Q 10/31/2024 |
| 7312024 | 9132024 | 10-Q 7/31/2024 |
| 4302024 | 6282024 | 10-K 4/30/2024 |
| 1312024 | 3082024 | 10-Q 1/31/2024 |
| 10312023 | 12082023 | 10-Q 10/31/2023 |
| 7312023 | 9012023 | 10-Q 7/31/2023 |
| 4302023 | 6302023 | 10-K 4/30/2023 |
| 1312023 | 3102023 | 10-Q 1/31/2023 |
| 10312022 | 12092022 | 10-Q 10/31/2022 |
| 7312022 | 9092022 | 10-Q 7/31/2022 |
| 4302022 | 7012022 | 10-K 4/30/2022 |
| 1312022 | 3112022 | 10-Q 1/31/2022 |
| 10312021 | 12172021 | 10-Q 10/31/2021 |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |